<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124954</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-05</org_study_id>
    <nct_id>NCT02124954</nct_id>
  </id_info>
  <brief_title>A Preliminary Drug Drug Interaction Study With TA-8995</brief_title>
  <official_title>A Phase I, Open Label Study to Assess the Effects of TA-8995 on the Pharmacokinetics of Midazolam and Digoxin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xention Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xention Ltd</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy males to look at how multiple doses of TA-8995 affect blood levels and
      rate of removal of other drugs, using single doses of digoxin and midazolam as examples, to
      see if there are any potential drug interactions that might affect patients in future
      studies.  The study will examine whether co-administration of TA-8995 affects the
      pharmacokinetics of digoxin and midazolam measured by area under the curve (AUC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Plasma concentrations of TA-8995, midazolam and digoxin</measure>
    <time_frame>Over 16 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pharmacokinetic Interactions</condition>
  <arm_group>
    <arm_group_label>Digoxin with/without TA-8995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam with/without TA-8995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <arm_group_label>Digoxin with/without TA-8995</arm_group_label>
    <arm_group_label>Midazolam with/without TA-8995</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam with/without TA-8995</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <arm_group_label>Digoxin with/without TA-8995</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy male subjects

        Exclusion Criteria

          -  Receiving any other drug therapy

          -  Clinically significant medical history

          -  Abnormal laboratory results or ECGs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Round</last_name>
    <phone>+44 (0) 1223 493900</phone>
    <email>info@xention.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
